CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Better Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Better Therapeutics Inc
548 Market St. #49404
Phone: (415) 887-2311p:415 887-2311 SAN FRANCISCO, CA  94101  United States Ticker: BTTXBTTX
This company ceased filing statements with the SEC on 5/30/2024.
Business Summary
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company, which is engaged in developing a software-based novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases (CMDx). Its platform allows for the creation of multiple PDTs that are designed to treat patients with CBT, delivered digitally via an app, to address the underlying causes of CMDx. Its lead PDT product candidate, AspyreRx, is a digital behavioral therapeutic delivering CBT for the treatment of a cardiometabolic disease. AspyreRx is a prescription-only digital treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D. Its pipeline also includes programs for the treatment of hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH) and chronic kidney disease.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks
7372 Prepackaged software

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Treasurer, Company Secretary, Director Craig R.Jalbert 61 3/14/2024 3/14/2024

Business Names
Business Name
BTTX
MCAD
MCADU

General Information
Number of Employees: 54 (As of 12/31/2022)
Outstanding Shares: 49,861,726 (As of 12/1/2023)
Shareholders: 62
Stock Exchange: OTC
Federal Tax Id: 853472546
Fax Number: (714) 978-2166


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025